Literature DB >> 9211832

Coordinated change between complement C1s production and chondrocyte differentiation in vitro.

K Nakagawa1, H Sakiyama, T Fukazawa, M Matsumoto, M Takigawa, T Toyoguchi, H Moriya.   

Abstract

In vitro synthesis of the first component of complement C1s was examined by using hamster epiphyseal chondrocytes (HAC) and human chondrosarcoma cell line HCS-2/8. Hamster and human C1s produced by the cells were quantified by immunoblotting and sandwich enzyme-linked immunosorbent assay (ELISA), respectively. It was possible to measure active and inactive C1s by sandwich ELISA, when we used anti-human C1s monoclonal antibodies, M241 recognizing only active C1s, and M365 and M81 recognizing both active and inactive C1s. Approximately 40% of C1s secreted from HCS-2/8 was found to be activated in the culture medium, whereas C1s from HAC was not. C1s production increased in accordance with chondrocyte differentiation induced by ascorbic acid. In contrast, transforming growth factor-beta1 and basic fibroblast growth factor, which inhibited differentiation, suppressed C1s production. These results confirmed our previous observation showing that C1s synthesis increased with differentiation into hypertrophic chondrocytes in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9211832     DOI: 10.1007/s004410050876

Source DB:  PubMed          Journal:  Cell Tissue Res        ISSN: 0302-766X            Impact factor:   5.249


  2 in total

1.  Complement C1s activation in degenerating articular cartilage of rheumatoid arthritis patients: immunohistochemical studies with an active form specific antibody.

Authors:  K Nakagawa; H Sakiyama; T Tsuchida; K Yamaguchi; T Toyoguchi; R Masuda; H Moriya
Journal:  Ann Rheum Dis       Date:  1999-03       Impact factor: 19.103

Review 2.  The complement cascade as a mediator of tissue growth and regeneration.

Authors:  Martin J Rutkowski; Michael E Sughrue; Ari J Kane; Brian J Ahn; Shanna Fang; Andrew T Parsa
Journal:  Inflamm Res       Date:  2010-06-02       Impact factor: 4.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.